BIOCRYST PHARM (BO1 MU) stock market data APIs
€7.5337
0(0%)
as of September 28, 2026
Try our APIs with
free plan!
BIOCRYST PHARM Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BO1.MU.
Prev. Close
7.5337
Open
7.5337
High
7.5337
Low
7.4644
52 wk Range
5.274-9.954
Market Cap
1 856 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOCRYST PHARM data using free add-ons & libraries
Get BIOCRYST PHARM Fundamental Data
BIOCRYST PHARM Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOCRYST PHARM News
New
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise...
Biopharma Stock With Layers of Technical Support in Place
After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been ...
4 Biotech Stocks to Watch as Potential Takeover Targets
M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain acc...
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug "Orladeyo," is looking to acquire mor...
Get BIOCRYST PHARM fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
